OK; here's the deal. 'Experimental' is government regulatory beaureaucratic speak... not that it's 'experimental'.
As best I recall from discussions with Dr. Luther a number of years ago... he and his group of researchers at LSU developed the vaccine back in the 1980s, sold it to Pitman-Moore, Inc., and shepherded it through the rigorous USDA licensure process. P-M was then bought out by Malinckrodt, which was subsequently purchased by Schering-Plough (which was later bought out by Merck, which is now Merial). S-P had previously had an Anaplasmosis vaccine which was a disaster, and they essentially said, "We are not going to offer another Anaplasmosis vaccine!", and released it back to the folks at LSU.
So, Dr. Luther and crew at University Products have been making & marketing it as an 'Experimental'/provisionally-licensed product, on a state-by-state basis(has to be approved for sale in a given state by its State Veterinarian) for many years.
Last time I spoke with him, he indicated that they were again working their way through the maze of USDA requirements in order to get the vaccine fully licensed again.
As previously discussed in this thread, the vaccine(above), if properly administered, does not prevent infection... it prevents clinical disease... vaccinated animals can become infected - but will not become clinically ill - and may serve as a source of infection for ticks feeding upon them, which may then amplify parasite numbers and infect naive animals in the herd upon subsequent feeding.
The A.marginale organism changes two of its six major surface proteins every 6 weeks or so, so infected animals are continually exposed to a 'new' strain of the organism. After that initial exposure and response, they're able to respond (immunologically) rapidly enough that no clinical illness is evident.